ROMANCE GOIM Trial Comparing Irinotecan Plus Cetuximab Rechallenge Versus TrifluridineTipiracil Plus Bevacizumab for Molecularly Selected Metastatic Colorectal Cancer
Led by Gruppo Oncologico Italia Meridionale · Updated on 2026-09-11
150
Participants Needed
26
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating two treatment options for patients with metastatic colorectal cancer whose disease has worsened after standard therapies. This phase II, open-label, multicenter clinical trial compares a rechallenge treatment using irinotecan plus cetuximab to the current standard of care, trifluridinetipiracil plus bevacizumab, as third-line therapy. Patients are selected based on specific molecular features of their cancer identified through circulating tumor DNA analysis from a blood sample. The main goal is to see if the rechallenge treatment results in a higher tumor response rate compared with the standard therapy.
Participants are randomly assigned to one of two groups. The experimental group receives cetuximab combined with irinotecan administered every two weeks. The control group receives oral trifluridinetipiracil on a cycle of 28 days along with bevacizumab every two weeks. Treatment continues until the disease worsens, side effects become unacceptable, or the participant chooses to stop. Tumor response is regularly checked using CT or MRI scans following RECIST criteria. After disease progression, switching to the other treatment may be considered.
During the trial, participants undergo scheduled tumor assessments, safety and tolerability monitoring, and quality of life questionnaires. Adverse events are tracked from the first dose until 30 days after the last dose. The study measures objective response rate primarily, as well as progression-free survival, overall survival, treatment exposure, and quality of life over up to 36 months. Long-term follow-up will assess survival outcomes, with treatments given under medical supervision until progression or withdrawal.
CONDITIONS
Brief Title
ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"
Research Team
D
Davide Ciardiello DC Principal Investigator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Eastern Cooperative Oncology Group Performance Status of 0 or 1
Histologically or cytologically confirmed colorectal cancer
At least one measurable lesion by RECIST 1.1
Wild-type KRAS/NRAS/BRAFV600E status in primary tumor or metastasis
Previous anti-EGFR therapy with at least partial response lasting 6 months or more
Progressed after anti-EGFR and irinotecan-free second-line treatment
At least 4 months since last anti-EGFR therapy
Refractory to 5-fluorouracil/capecitabine, irinotecan, oxaliplatin, and bevacizumab
Molecular profiling showing wild-type RAS, BRAF, EGFR, PIK3CA exon 20, MAP2K1, MET, and no HER2 amplification in circulating tumor DNA
Life expectancy of at least 3 months
Adequate blood, liver, and kidney function
No contraindications to study drugs
No prior treatment with trifluridine/tipiracil
Women of childbearing potential with negative pregnancy test and agreeing to contraception
Males agreeing to contraception
Ability and willingness to comply with study protocol
Signed informed consent
You will not qualify if you...
Eastern Cooperative Oncology Group Performance Status of 2 or higher
More than 2 prior lines of treatment for metastatic disease
Previous treatment with trifluridine/tipiracil
Molecular profiling showing RAS/BRAF/EGFR/PIK3CAex20/MAP2K1/MET mutations or HER2 amplification
History of other malignancies within past 2 years except certain localized cancers
Bleeding disorders or coagulopathy
Uncontrolled high blood pressure or history of hypertensive crisis
Severe allergic reactions to study drugs or uncontrolled asthma
Significant heart disease, active inflammatory bowel or autoimmune disease
Interstitial pneumonitis or pulmonary fibrosis
Recent abdominal fistula, GI perforation, abscess, or bleeding within 6 months
Pregnancy or breastfeeding
Psychiatric or addictive disorders preventing participation
Active uncontrolled infections or other illnesses contraindicating study treatments
Withdrawal of consent
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Treatment
Duration - Up to approximately 24 months
Participants receive either irinotecan plus cetuximab or trifluridine/tipiracil plus bevacizumab until disease progression, unacceptable side effects, or withdrawal.
Treatment administered every two weeks or in 28-day cycles with regular tumor assessments
Follow-up
Duration - Up to 36 months
Participants are monitored for survival outcomes and safety after treatment ends.
Regular follow-up visits for survival and safety assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Randomized Study Comparing 5-FluorouracilLeucovorin Plus Regorafenib Versus Trifluridine-Tipiracil With Bevacizumab in Metastatic Colorectal Cancer
Phase 1b Study of HS-20093 Combined With Other Cancer Drugs for Advanced Metastatic Colorectal Cancer
Evaluating Safety and Effectiveness of ctDNA-Guided Anti-EGFR Retreatment in Real-World Metastatic Colorectal Cancer Patients
Phase 1 Study of BBO-11818 Alone and With Other Treatments in Adults with Advanced KRAS Mutant Cancers
Phase II Trial of Fruquintinib and Cetuximab-beta Combination for Third-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer
Evaluating HSK42360-Na Tablets Plus Cetuximab With or Without Chemotherapy for BRAF V600-Mutant Metastatic Colorectal Cancer
Comparing NALIRIFOX Plus Targeted Therapy to FOLFOX Plus Targeted Therapy
as First Treatment for Inoperable Metastatic Colorectal Cancer
in a Phase 3 Randomized Study
Phase IbII Study of Nelmastobart with TrifluridineTipiracil and Bevacizumab for Adults with Metastatic or Recurrent Colorectal Cancer Resistant to Oxaliplatin and Irinotecan Chemotherapy
Evaluating Cannabidiol CBD to Prevent Oxaliplatin-Induced Nerve Damage in Metastatic Colorectal Cancer Patients Receiving Chemotherapy
Node-Sparing Short-Course Radiotherapy Combined with Chemotherapy, Bevacizumab, and PD-1 Inhibitor Versus Chemotherapy and Bevacizumab Alone
for Metastatic pMMRMSS Colorectal Cancer A Randomized Phase IIIII Study
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab as Third-Line Treatment in Circulating Tumor DNA-Selected Metastatic Colorectal Cancer (ROMANCE Trial).
Alessandra Pia D'Agata, Gloria Pellizzari, Giulia Martini...